196 related articles for article (PubMed ID: 34139789)
41. [Classical medications in the treatment of inflammatory bowel diseases].
Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
[TBL] [Abstract][Full Text] [Related]
42. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy.
Sridhar S; Maltz RM; Boyle B; Kim SC
Inflamm Bowel Dis; 2018 Aug; 24(9):2086-2092. PubMed ID: 29718343
[TBL] [Abstract][Full Text] [Related]
43. Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents.
Guerra I; Gisbert JP
Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):41-8. PubMed ID: 23265148
[TBL] [Abstract][Full Text] [Related]
44. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
45. Monitoring for Extra-Intestinal Cancers in IBD.
Sifuentes H; Kane S
Curr Gastroenterol Rep; 2015 Nov; 17(11):42. PubMed ID: 26364836
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetics of inflammatory bowel disease.
van den Bosch BJ; Coenen MJ
Pharmacogenomics; 2021 Jan; 22(1):55-66. PubMed ID: 33305616
[TBL] [Abstract][Full Text] [Related]
47. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?
Lawrance IC
World J Gastroenterol; 2014 Feb; 20(5):1248-58. PubMed ID: 24574799
[TBL] [Abstract][Full Text] [Related]
48. Cutaneous adverse effects of biologic medications.
Pasadyn SR; Knabel D; Fernandez AP; Warren CB
Cleve Clin J Med; 2020 May; 87(5):288-299. PubMed ID: 32357984
[TBL] [Abstract][Full Text] [Related]
49. Comparison table: some drugs for inflammatory bowel disease.
Med Lett Drugs Ther; 2018 Jul; 60(1550):e117-e122. PubMed ID: 30036356
[No Abstract] [Full Text] [Related]
50. [Perspectives in inflammatory bowel diseases treatment].
Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
[TBL] [Abstract][Full Text] [Related]
51. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature.
Hagen JW; Pugliano-Mauro MA
Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147
[TBL] [Abstract][Full Text] [Related]
52. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
53. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
54. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
55. Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective.
Thebeau M; Rubin K; Hofmann M; Grimm J; Weinstein A; Choi JN
J Am Assoc Nurse Pract; 2017 May; 29(5):294-303. PubMed ID: 28436601
[TBL] [Abstract][Full Text] [Related]
56. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
[TBL] [Abstract][Full Text] [Related]
57. [What's new in dermatological treatments?].
Martin L
Ann Dermatol Venereol; 2010 Dec; 137 Suppl 4():S165-76. PubMed ID: 21193120
[TBL] [Abstract][Full Text] [Related]
58. Do inflammatory bowel disease therapies cause cancer?
Mason M; Siegel CA
Inflamm Bowel Dis; 2013 May; 19(6):1306-21. PubMed ID: 23470503
[TBL] [Abstract][Full Text] [Related]
59. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease.
Kolho KL; Ruuska T; Savilahti E
Acta Paediatr; 2007 Jan; 96(1):128-30. PubMed ID: 17187619
[TBL] [Abstract][Full Text] [Related]
60. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
Godat S; Fournier N; Safroneeva E; Juillerat P; Nydegger A; Straumann A; Vavricka S; Biedermann L; Greuter T; Fraga M; Abdelrahman K; Hahnloser D; Sauter B; Rogler G; Michetti P; Schoepfer AM;
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):612-620. PubMed ID: 29384798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
